An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to Levodopa

Trial Profile

An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to Levodopa

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs AAV-hAADC (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Proof of concept
  • Sponsors Voyager Therapeutics
  • Most Recent Events

    • 09 Mar 2018 Longer term results published in a Voyager Therapeutics media release.
    • 02 Nov 2017 According to a Voyager Therapeutics media release, data from this trial was presented at the European Society of Gene and Cell Therapy (ESGCT) 2017.
    • 06 Oct 2017 According to a Voyager Therapeutics media release, data from this trial will be presented at the Congress of the European Society of Gene and Cell Therapy (ESGCT) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top